cyrilzakka/clinical-trials huggingface dataset:
Considering Peripheral Nerve Injury, Is It Safe to Perform Transradial Angiography?

So far, apart from a limited number of case reports and small-scale studies, the frequency and severity of this complication have not been objectively evaluated using electromyography (EMG). In this study, presence, severity, and extent of nerve injury (one of the potential complications following the transradial approach (TRA)) were evaluated by EMG studies in patients managed at Bursa City Hospital.

Evaluation of peripheral nerve injury after transradial angiography with nerve conduction studies.

Eligibility Criteria:
Inclusion Criteria:

20-60 years old patiens who applied trans angiograhy were included to study

Exclusion Criteria:

* Having cognitive disorders
* Patients who have story of cardiac pace / ICD,
* History of polyneuropathy,
* Previous nerve damages,
* Deformities on arm,
* Plexopathy,
* Radiculopathy,
* Spinal surgery.
* Having medical treatment for any kind of neuropathy
* Having Cognitive disorders
Anti-psychotic Medication (New Use) Weight Loss Study

This is a pilot study to determine the safety and efficacy of an investigational product (IHBG-10) on weight change and changes in body composition in subjects who have just started taking (for less than three months) certain anti-psychotic medications (Risperdal, Seroquel, and/or Zyprexa).

A total of 30 subjects will be enrolled in this study. They will be randomized in to one of two groups. One group (of 20 subjects) will take 500 mg of the investigational product (IHBG-10) 15 minutes prior to the three main meals of the day; subjects will continue to take their prescribed anti-psychotic medications. The other group (of 10 subjects) will take a placebo 15 minutes prior to the three main meals of the day; subjects will continue to take their prescribed anti-psychotic medications. Subjects will take the investigational product or placebo for 12 weeks. Participation in this study involves 4 study visits.

Eligibility Criteria:
Inclusion Criteria:

* Men and women, age 18 and older
* Agree to keep diet, exercise and all current health habits stable during participation in the study
* Have been taking Risperdal (Risperidone), Seroquel (Quetiapine), or Zyprexa (Olanzapine) for less than 3 months

Exclusion Criteria:

* Current active acute psychotic episode
* Women who are pregnant, breastfeeding or planning to become pregnant
* Prior bariatric surgery
* Use of prescription or over-the-counter appetite suppressants, herbal products or other medications for weight loss within the past month
* Obesity as a result of a clinically-diagnosed endocrine problem
Adjuvant Anti-Recurrence Treatment With Rapamycin on Early-stage HCC

To evaluate the clinical effect of rapamycin combined with TACE on early-stage HCC with overexpression of ASPH after radical surgery using randomized controlled study and provide a new anti-recurrence treatment for HCC patients after operation.


Eligibility Criteria:
Inclusion Criteria:

1. Via clinical diagnosis and confirm it is primary liver cancer
2. Pathological evidence of HCC
3. Estimate tumor can gain treatment of curing operation
4. No evidence for extrahepatic metestasis
5. liver function ：Child-Pugh A/B
6. BCLC stage：0/1；TNM stage：Ⅰ

Exclusion Criteria:

1. reject to attend；
2. impossible to come to our hospital for physical examination regularly.
3. cancer epitome、seed focus、lymph node or distant metastasis
4. Blood clotting function hindrance; 5, Patients with other diseases which may affect the treatment mentioned.
Impact of Diet and Exercise Activity on Pregnancy Outcomes

The general goal of the present study is to assess the impact of a community-based exercise and dietary intervention in pregnant women living in urban areas during and after their pregnancy on the reduction of the risks of both diabetes and obesity in mothers and their offspring.

We hypothesize that a community-based lifestyle intervention program during and after gestation may improve pregnancy outcomes in terms of reducing the risk of developing obesity or type 2 DM in mothers and their children.

Impact of lifestyle intervention on excessive gestational weight gain

Eligibility Criteria:
Inclusion Criteria:

* Pregnancy \< 20 weeks.
* Expressed interest in study and willingness to consent to participate in the study.

Exclusion Criteria:

* Obstetric or medical contraindications for exercise according to 2002 SOCG guideline (ruptured membranes, preterm labor, incompetent cervix, hypertensive disorders of pregnancy, growth restricted fetus, placenta previa, persistent bleeding in 2nd or 3rd trimester, significant metabolic, cardiovascular, respiratory or systemic disorder) (5, 6).
* Pre-existing diabetes (except a history of GDM, but not in current pregnancy).
* Multiple gestations.
MCE-new for Detection of Gastric Lesions

Clinical application of magnetically controlled capsule endoscopy : a prospective self-controlled trial

The aim of this study is to investigate the effectiveness and safety of using a new MCE system for routine gastric examination and automatic scanning. This study is a prospective, self controlled clinical trail, which includes adult patients who plan to undergo MCE examination. Patients will undergo three different tests during the experiment: NaviEC-2000Pro Gastro Scan, NaviEC-2000Pro routine gastric examination, NaviEC-1000 routine gastric examination.

Eligibility Criteria:
Inclusion Criteria:

* underwent gastric examination;
* At least 18 years old；
* Be able to provide informed consent.

Exclusion Criteria:

* With swallowing obstruction or disorders;
* With known or suspected gastrointestinal obstruction, stenosis and fistula;
* Have no conditions for surgery or refuse to undergo any abdominal surgery;
* Be allergic to or have other known contraindication or intolerance to the drug used in the study;
* With pacemakers or other electronic devices such as electronic cochlear implants, implanted magnetic metal drug infusion pumps, neurostimulators, and magnetic metal foreign bodies;
* Women during pregnancy;
* Currently enrolled in another clinical trial of a drug or device;
* Other conditions determined by the investigator to be inappropriate for enrollment.
Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure

The purpose of this phase II, randomized, double-blind placebo controlled, multi-center study is to evaluate the safety and efficacy of 10 mg atrasentan in hormone naive subjects as measured by rate of rise in the PSA (primary objective).


Eligibility Criteria:
Inclusion Criteria:

* prostate adenocarcinoma,
* radical prostatectomy,
* PSA between 0.4 and 5 ng/mL,
* PSADT \< 1 year

Exclusion Criteria:

* previous hormonal therapy,
* salvage therapy to the pelvis within 3 months prior to randomization
Effectiveness of Adding Subcutaneous Long-Acting Detemir to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy

The investigators anticipate that the use of Detemir will decrease the duration of an insulin drip, the dose of short-acting insulin in the drip, hospital and ICU (intensive care unit) length of stay, improve glycemic control, and prevent rebound hyperglycemias when the insulin drip is discontinued.


Eligibility Criteria:
Inclusion Criteria:

* Diabetic ketoacidosis (DKA) and hyperosmolar non-ketotic states, hyperglycemia with severe illness, pre-and postoperative states, nothing by mouth (NPO), as well as gastric (tube feeding) and parenteral nutritional requiring insulin drip.
* Patients with type 1 and type 2 diabetes mellitus (DM) will be included.
* Patient with both types of diabetes will be among those treated with insulin drip while being NPO, having severe concomitant illness or receiving enteral and parenteral nutrition
* Patients will be of age 19 to 80.

Exclusion Criteria:

* Inability to consent for the study for any reason including cognitive impairment secondary to hyperglycemia, presence of severe medical conditions requiring intubation, severe sepsis, hypothermia, and anticipated length of insulin drop 2 weeks and longer, pregnancy, Levemir allergy, and concurrent sulfonamide treatment
E-Learning During COVID-19 Pandemic: Turning a Crisis Into Opportunity

E-learning is now a well-established method of education all over the world, and it has been used for years as a major method of teaching in many fields. The medical field is not far away, but the use of e-learning in it has become increasing, and the technological advances have made this process more realistic and interactive.

The emergence and spread of COVID-19 virus as a global pandemic has placed many restrictions on daily life activities including enrolment in schools and universities in many countries, including Jordan, which has led to a marked and increased use of e-learning as a significant alternative to traditional education. Medical teaching has some peculiar characteristics, especially the need for direct interaction between the student and the patient, attending clinics, wards, and operating rooms, and the close exposure to clinical cases. This have created some restrictions and obstacles in the way of using e-learning in medicine education, in addition to other important influencing and limiting barriers, such as technical barriers, especially in the light of the abrupt transition to e-learning utilization under the current circumstance, and the psychological barriers -in terms of anxiety and stress- that resulted by this pandemic and the consequent home quarantine.

This cross-sectional study aims to study the current state of e-learning in the School of Medicine at the University of Jordan, by evaluating the teaching tools used and the effect of the rapid transition in basic medical teaching and clinical medical training to become mainly based on the e-learning methodology on the academic achievement and assimilation of the clinical part of the medical courses, and the general satisfaction of the medical students at their different academic levels. Other influencing factors will be studied, such as the extent of students' readiness and preparedness to use the e-learning tools and their previous experience in it, the extent of the readiness and experience of their teachers, and the general mental health status of students and their effects on accepting the distance e-learning process, and the commitment to participate and interact with various electronic activities.

This study, after exploring the difficulties and hurdles facing the e-learning process and after analysis, aims to propose practical solutions to facilitate and maintain it beyond the COVID-19 pandemic era.


Eligibility Criteria:
Inclusion Criteria:

* All Medical Students

Exclusion Criteria:

* None
Mitigating Response to Stressors in Pregnant Women

Stress-induced pregnancy complications are significant contributors to preterm labor as well as maternal and perinatal morbidity and mortality. The goals of this study are two folds: first it aims to capture the pregnant woman's journey to seek and receive prenatal care. Second, this study aims to develop models that 1) assess the adverse health and biological effects of social factors on pregnant women who experience repeated or chronic stress, 2) address how stress can be mitigated in pregnant women from different backgrounds who experience high stress.

Maternal stress-induced complications are correlated with gestational hypertension, infant low birth weight, and developmental disruption. Various social determinants of health are contributors to stress in pregnant women; factors such as socioeconomic status, education, access to prenatal care, and neighborhood conditions are some of the most identified psychosocial causes of prenatal stress. Further, chronic psychosocial stress is identified as a significant contributor to biophysiological damages such as accelerated telomere shortening in the mother as well as the offspring. Using a public health approach, this research study proposes to gather evidence to assess how response to stress is modulated and how it is captured in and affects pregnant women, with history of prolonged exposure to harmful stressors. More relevant to this study, individuals who have repeated exposure to stressors have poorly managed response to stress and display frequent elevated heart rates due to biological and physiological disruptions. Evidence from the literature suggests that having a support system and utilizing stress management techniques moderate and buffer the effects of stress on physiological measures while facilitating emotional recovery.

Eligibility Criteria:
Inclusion Criteria: in 24 weeks gestation or more

* between 21 and 37 years of age

Exclusion Criteria:

* in less than 24 weeks gestation
* high risk pregnancies
Vertical Versus Horizontal Plicataion in Transperienal Repair of Rectocele

We assumed that the technique of plication of the rectovaginal septum and rectal wall may factor in providing better and more sustained repair that confers more satisfactory improvement in symptoms. The present randomized study aimed to evaluate the outcome of TPR with vertical plication of the rectovaginal septum as compared to the horizontal plication with regards to improvement in ODS, recurrence of rectocele, postoperative complications and dyspareunia.


Eligibility Criteria:
Inclusion Criteria:

* Vertical plication of the rectovaginal septum was done

Exclusion Criteria:

* patients with ODS caused by conditions other than rectocele such as anismus and internal rectal prolapse
* patients with slow transit constipation.
* patients with recurrent rectocele after previous surgery.
* patients with pre-existing FI
* patients with associated anorectal pathology.
Celgosivir as a Treatment Against Dengue

This is a Randomized, Double-Blind, Placebo-Controlled, Phase 1b Clinical Study to Evaluate the Activity, Pharmacokinetics, Safety and Tolerability of Celgosivir in Adults with Confirmed Dengue Fever.

Patients with confirmed dengue fever who meet all inclusion and exclusion criteria will be enrolled and admitted to the Investigational Medicine Unit. Patients will be randomized 1:1 to celgosivir or placebo. Capsules of placebo or celgosivir will be administered for 5 days. While in hospital, daily clinical exams will be conducted, and blood samples will be collected for viral load, quantitative NS1, hematology, clinical chemistry, cytokine levels and pharmacokinetics (PK). Safety assessments will be conducted. At discharge on Study Day 5, patients will be asked to return on Study Days 7, 10, and 15 for blood sampling and safety assessments.

Eligibility Criteria:
Main Inclusion Criteria:

* Fever of ≥ 38°C of ≤ 48 hr duration.
* At least two of the following criteria indicating probable dengue infection:

  * Live or work in or recent travel to dengue endemic area
  * Nausea and vomiting
  * Presence of rash
  * Aches and pains, including headache, or retro-orbital, muscle or joint pain
* Positive NS1 strip assay

Main Exclusion Criteria:

* Clinical signs and symptoms for severe dengue
* Patients with certain abnormal laboratory values
* History of presently active intestinal disorders
* Severe diarrhea
* Current usage of anticoagulant drugs
* Other clinically significant acute illness
* History of severe drug and/or food allergies
* Exposure to investigational agent within 30 days prior to study drug administration
* Clinically significant abnormal physical exam unrelated to dengue fever
* Pregnancy
Effect of Sofosbuvir-daclatasuvir on Angiogenesis

The study aimed at study of the Effect of Daclatasvir Plus Sofosbuvir on Angiogenesis in Egyptian Patients With Chronic HCV Infection

The study primary aim was at evaluation of the Effect of Daclatasvir Plus Sofosbuvir on Angiogenesis in Egyptian Patients With Chronic HCV Infection

Eligibility Criteria:
Inclusion Criteria:

* Chronic HCV patients

Exclusion Criteria:

* HCC.
* HIV or HBV.
* Malignancy.
* Pregnancy.
Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients

The purpose of this study is to estimate the effect of AZD3355 as an add-on treatment to a Proton Pump Inhibitor (PPI) on Gastroesophageal reflux disease (GERD) symptoms in patients with an incomplete response to PPI treatment.


Eligibility Criteria:
Inclusion Criteria:

* Provision of written informed consent
* At least 6 months history of Gastroesophageal reflux disease (GERD) symptoms
* Continuous treatment with Proton Pump Inhibitor (PPI)
* Ability to read and write

Exclusion Criteria:

* Prior surgery of the upper gastrointestinal (GI) tract
* History of clinically significant diseases other than GERD
* Need for concomitant medication with drugs that may influence gastrointestinal symptoms
Neuroinflammation in Asymptomatic Carotid Artery Disease - Imaging Substudy

This clinical imaging substudy will use the small molecule translocator protein (TSPO) ligand, Fludeoxyglucose(18F)-labeled DPA-714, to compare neuroinflammation in individuals with high or low grade asymptomatic carotid artery stenosis (aCAD) who are participating in the separate Neuroinflammation in Asymptomatic Carotid Artery Disease study lead by Dr. Ron Lazar (IRB-300007806). The positron emission tomography (PET) tracer \[18F\]DPA-714 binds to the 18 kDa translocator protein (TSPO, also known as the peripheral benzodiazepine receptor) in the mitochondria of activated microglia/macrophages and provides a non-invasive measure of neuroinflammation.


Eligibility Criteria:
Inclusion Criteria:

Cohort 1 - Critical Asymptomatic Carotid Stenosis Group Inclusion Criteria:

1. Critical Stenosis Group: Diagnosis of Asymptomatic Carotid Artery Disease (aCAD) with \>70% stenosis or peak systolic velocity on DUS ≥ 230 cm/s plus CTA or MRA confirmation.
2. Participation in University of Alabama at Birmingham (UAB) IRB protocol "Neuroinflammation in Asymptomatic Carotid Artery Disease" (IRB-300007806, PI Lazar).
3. Male or female age \>18 years
4. English speaking with at least 8th grade education
5. High affinity binder for TSPO ligands based on genotyping for single nucleotide polymorphism (SNP) rs6971
6. Planned revascularization for aCAD in \>14 days from time of consent

Cohort 2 - Non-Critical Asymptomatic Carotid Stenosis Group Inclusion Criteria:

1. Participation in UAB IRB protocol "Neuroinflammation in Asymptomatic Carotid Artery Disease" (IRB-300007806, PI Lazar).
2. \<40% carotid stenosis
3. No planned revascularization
4. Male or female age 18 or older
5. English speaking with at least 8th grade education
6. High affinity binder for TSPO ligands based on genotyping SNP rs6971

Exclusion Criteria:

1. Contraindication to MRI
2. Pregnancy or lactation
3. Previous revascularization for treatment of aCAD
4. Prior stroke
5. Severe anemia (blood hemoglobin ≤ 8 mg/dL)
6. Previously obtained MRI scan with evidence of clinically significant abnormality
7. History of traumatic head injury defined by loss of consciousness \>30 minutes or seizure at the time of the injury
8. Major depression
9. Known history of dementia
10. Serious medical comorbidity that, based on the judgement of the principal investigator, may interfere with study participation
11. Low or mixed-affinity binding for TSPO ligands based on genotyping for SNP rs6971.
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy

The purpose of this study is to evaluate the efficacy of inotuzumab ozogamicin plus rituximab in relapsed/refractory aggressive Non-Hodgkin lymphoma patients who are not candidates for intensive high-dose chemotherapy. Specifically, the goal is to demonstrate the superiority of this combination compared with an active comparator arm (investigator's choice of rituximab+bendamustine or rituximab+gemcitabine) using the primary endpoint of overall survival.


Eligibility Criteria:
Inclusion Criteria:

-

Exclusion Criteria:

-
Cancer Sensing: Evaluation of Odour Sampling Techniques

To evaluate the suitability of two odour capturing techniques for early detection of skin cancer.

The study will investigate the suitability of two odour capturing techniques for early detection of skin cancer. The techniques to capture VOCs are: a) solid phase microextraction (SPME) and b) collection of VOCs via an adsorptive patch, worn on the skin. The objective is to evaluate the suitability of two techniques for collecting VOCs.

Odour samples from cancerous and healthy skin will be captured using the two non-invasive techniques. The techniques will initially be tested in a laboratory environment. They will then be applied in parallel to patients and healthy people. VOC compounds of odour samples will be analysed for their profiles in respect of cancerous and healthy skins. The VOCs profiles will be recorded in a VOC bank for future analysis.

Following the initial tests, patients (n=20) with skin cancer will be recruited from Poole and Dorset County Hospitals. Arrangement will be made to obtain odour samples by positioning patches on the cancerous skin sites (for approximately 30 minutes) of patients and recover them. To obtain samples from healthy people (n=10), staff and students within the university are invited to participate in this research by providing odour samples from their skins using the same type of patches.

In parallel, VOCs from skin cancer patients will also be collected from patients with the SPME fibres described earlier. The SPME device is roughly equivalent in size and shape to a ballpoint pen, from the tip of which an adsorbent fibre can be extended. The SPME device is held statically with a flexible clamp (a weighted clamp which rests on a bench / desk near the patient), and is positioned so that the tip of the fibre rests close to, but not touching, the affected skin area. The fibre needs to be held in place to sample the air above the affected skin for a pre-determined period of time, likely to be 15 - 30 minutes. Specifics such as the sampling time and related factors will be evaluated during the initial laboratory testing. Following the defined time period of sampling, the fibre is retracted into the body of the SPME device (to protect it), and the device is returned to the laboratory for analysis. The high temperatures involved in GCMS analysis cause VOCs captured by the SPME device to be released (desorbed) and they are subsequently swept through the GCMS system for analysis.

The VOC samples from both the techniques will be transported to Bournemouth university for analysis.

The outcome will be the identification of the most suitable VOC collection technique (SPME vs patch) by comparing the VOC profiles of cancerous and healthy skin.

Eligibility Criteria:
Inclusion Criteria:

* Patients diagnosed with skin cancer, able to speak and understand written English,
* 18 years or older and
* Capable of giving informed consent.

Exclusion Criteria:

* Patients too weak to speak or give written informed consent;
* Non-English speaking without an interpreter;
* Patients lacking mental capacity to consent, or
* Below the age of 18.